Phase 1 trial of VRDN-003 in healthy volunteers
Latest Information Update: 26 Nov 2024
At a glance
Most Recent Events
- 18 Dec 2023 According to a Viridian Therapeutics Media Release, the company announced the selection of VRDN-003 as its lead subcutaneous (SC) program for thyroid eye disease (TED) based on positive data from a Phase 1 clinical study in healthy volunteers.
- 18 Dec 2023 Results presented in a Viridian Therapeutics Media Release.
- 08 Aug 2023 According to a Viridian Therapeutics media release topline results from this study are expected n the fourth quarter of 2023